Who is sponsoring NCT03836599?

NCT03836599 is sponsored by AstraZeneca.

What condition does NCT03836599 study?

NCT03836599 studies Chronic Kidney Disease.

What drugs are being tested in NCT03836599?

Interventions: Verinurad, Allopurinol, Placebo.

What is the status of NCT03836599?

NCT03836599 is currently COMPLETED.

Last reviewed 2019-05-13 · How we verify

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599 PHASE1 COMPLETED

This is a randomized, placebo controlled, double-blind study with two separate cohorts to assess safety, tolerability and pharmacokinetics of verinurad and allopurinol in healthy subjects. In cohort 1, twelve Asian subjects will be treated with allopurinol 300mg for 7 days followed by either allopurinol 300mg and verinurad 24mg or matching placebo for 7 days. In Cohort 2, nine Chinese subjects will be treated with allopurinol 300mg for 7 days followed by allopurinol 300mg and verinurad 12mg administered on 7 out of 8 days.

Details

Lead sponsor	AstraZeneca
Phase	PHASE1
Status	COMPLETED
Enrolment	6
Start date	Wed Jan 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Apr 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Chronic Kidney Disease

Interventions

Verinurad
Allopurinol
Placebo

Countries

United States